| dc.contributor.author | Ecder, Tevfik | |
| dc.date.accessioned | 2019-08-13T12:10:23Z | |
| dc.date.accessioned | 2019-08-13T15:57:06Z | |
| dc.date.available | 2019-08-13T12:10:23Z | |
| dc.date.available | 2019-08-13T15:57:06Z | |
| dc.date.issued | 2016 | |
| dc.identifier.issn | 0931-0509 | |
| dc.identifier.issn | 1460-2385 | |
| dc.identifier.uri | https://dx.doi.org/10.1093/ndt/gfv449 | |
| dc.identifier.uri | http://hdl.handle.net/11446/2450 | |
| dc.description | WOS: 000383285500002 | en_US |
| dc.description | PubMed ID: 26908774 | en_US |
| dc.description.abstract | aEuro broken vertical bar Will statins take a place in the therapeutic armamentarium of ADPKD? We need large randomized controlled trials to give a clear answer to this question. Until we get this evidence, the decision to use a statin in the management of patients with ADPKD will remain with the physician.aEuro broken vertical bar. | en_US |
| dc.language.iso | eng | en_US |
| dc.publisher | OXFORD UNIV PRESS | en_US |
| dc.identifier.doi | 10.1093/ndt/gfv449 | en_US |
| dc.rights | info:eu-repo/semantics/openAccess | en_US |
| dc.title | Statins in the treatment of autosomal dominant polycystic kidney disease | en_US |
| dc.type | article | en_US |
| dc.relation.journal | NEPHROLOGY DIALYSIS TRANSPLANTATION | en_US |
| dc.department | DBÜ | en_US |
| dc.identifier.issue | 8 | en_US |
| dc.identifier.volume | 31 | en_US |
| dc.identifier.startpage | 1194 | en_US |
| dc.identifier.endpage | 1196 | en_US |
| dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
| dc.department-temp | [Ecder, Tevfik] Istanbul Bilim Univ, Div Nephrol, Dept Internal Med, Fac Med, Istanbul, Turkey | en_US |
